BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 12203115)

  • 1. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q; Luo X; Huang Y; Sheikh MS
    Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
    He Q; Huang Y; Sheikh MS
    Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis.
    He Q; Montalbano J; Corcoran C; Jin W; Huang Y; Sheikh MS
    Oncogene; 2003 May; 22(17):2674-9. PubMed ID: 12730681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
    Ravi R; Bedi A
    Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.
    Huang Y; He Q; Hillman MJ; Rong R; Sheikh MS
    Cancer Res; 2001 Sep; 61(18):6918-24. PubMed ID: 11559570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
    Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
    Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.
    Tang X; Sun YJ; Half E; Kuo MT; Sinicrope F
    Cancer Res; 2002 Sep; 62(17):4903-8. PubMed ID: 12208739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.
    Sinicrope FA; Penington RC
    Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
    Totzke G; Schulze-Osthoff K; Jänicke RU
    Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line.
    Han Z; Pantazis P; Wyche JH; Kouttab N; Kidd VJ; Hendrickson EA
    J Biol Chem; 2001 Oct; 276(42):38748-54. PubMed ID: 11514566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
    LeBlanc H; Lawrence D; Varfolomeev E; Totpal K; Morlan J; Schow P; Fong S; Schwall R; Sinicropi D; Ashkenazi A
    Nat Med; 2002 Mar; 8(3):274-81. PubMed ID: 11875499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.
    Deng Y; Lin Y; Wu X
    Genes Dev; 2002 Jan; 16(1):33-45. PubMed ID: 11782443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
    He Q; Lee DI; Rong R; Yu M; Luo X; Klein M; El-Deiry WS; Huang Y; Hussain A; Sheikh MS
    Oncogene; 2002 Apr; 21(17):2623-33. PubMed ID: 11965535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
    Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
    Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.